Cantargia ABCHIX:CANTAS 37 Net Margin % is -6,490.16% as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, Cantargia AB ranks better than 95.24% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cantargia AB's Net Income for the
three
months ended in Mar. 2026 was kr-33.0 Mil. Cantargia AB's Revenue for the
three
months ended in Mar. 2026 was kr0.5 Mil. Therefore, Cantargia AB's net margin for the quarter that ended in Mar. 2026 was -6,490.16%.
The historical rank and industry rank for Cantargia AB's Net Margin % or its related term are showing as below:
CHIX:CANTAs'
s Net Margin % Range Over the Past 10 Years
Min: 46.41 Med: 46.41 Max: 50.73
Current: 50.73
CHIX:CANTAs's Net Margin % is ranked better than 95.24% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs CHIX:CANTAs: 50.73
Cantargia AB (CHIX:CANTAs) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cantargia AB Net Margin % Related Terms
Cantargia AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Cantargia AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Cantargia AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cantargia AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a Net Margin % of -6,490.16% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cantargia AB and its competitors. Over the past decade, Cantargia AB's Net Margin % has ranged from 46.41 to 50.73. According to the industry distribution chart, Cantargia AB ranks #45 out of 946 companies in the Biotechnology industry, placing it in the top 4.8%.
Is Cantargia AB's Net Margin % too high?
Cantargia AB's current Net Margin % is -6,490.16%. Over the past 10 years, this metric has ranged from a low of 46.41 to a high of 50.73. Based on the distribution chart, Cantargia AB ranks #45 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #45 out of 946 companies for Net Margin %. This places Cantargia AB in the top 5% of its industry — outperforming the majority of peers. Historically, Cantargia AB's own Net Margin % has ranged from 46.41 to 50.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cantargia AB and its competitors. Cantargia AB's current Net Margin % is -6,490.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Net Margin % of -6,490.16%. The current Net Margin % is -6,490.16%. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Net Margin % is -6,490.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
